Ratings of the clinical global impression of improvement after the treatment showed the following significant results for the treatment group vs. placebo group: very much improved (50.9% vs. 18.5%), much improved (22.6% vs. 29.6%), small improvement (18.9% vs. 14.8%), and unchanged or deterioration (7.5% vs. 37.0%) (χ2 = 26.559; P < 0.001).
The outcome of the specific inflammatory signs was scored as resolved if complete clearance of the specific inflammatory activity was seen; partial response if the specific inflammatory activity had decreased; stabilization if the specific inflammatory activity remained unchanged and deterioration if the specific inflammatory activity had increased.
Comparable to the traditional RAMRIS, the foot subscore of the new HaF-score uncovered 6 out of 15 patients with unchanged values or deterioration in spite of clinical improvement (i.e. foot joint count) (Table 5).
There were 886 participants with their glycaemic status (normal glucose tolerance [NGT] or impaired fasting glucose [IFG]/impaired glucose tolerance [IGT]) remaining unchanged, 206 participants with deterioration of glycaemia (i.e. from NGT to IFG/IGT or diabetes, or from IFG/IGT to diabetes) and 196 participants with improved glycaemia (from IFG/IGT to NGT).
At follow-up 15.3% of patients reported complete symptom resolution, 59.3% improvement, 22% unchanged symptoms, and 3.4% deterioration.
This event cannot be considered unfavorable, since it denounces a condition of hyperfiltration of the kidney, probably, if left unchanged, able to induce a deterioration of renal function with time.
About 25% of the patients reported either a clinically important deterioration or remained unchanged with between 40 and 49% of the patients reporting a clinically important improvement on the MacNew HRQL scale scores.
The elevated urea and ammonia levels did not reach worrisome levels and were not associated with signs of neurologic and metabolic deterioration as ICP remained unchanged, and glutamate was significantly decreased in the face of stable brain metabolism reflected by unchanged cerebral lactate and lactate-to-pyruvate ratio.
Two weeks after injection, in the MI+V animals, the morpho-functional properties of the left ventricle either remained unchanged or underwent a slight further deterioration (Table S2).
Stabilization of the patients' condition was defined as an unchanged or decreased SOFA score, and deterioration was defined as an increased SOFA score.
However, the fact that other characteristics of the population (especially age) remain unchanged over time makes the real health deterioration scenario unlikely.
